ARTICLE | Clinical News
IMG-7289: Ph I/II started
November 10, 2016 11:20 PM UTC
Imago began an open-label, Australian Phase I/II trial to evaluate oral IMG-7289 with and without tretinoin in 30 patients. The dose-escalation Phase I portion will identify the selected dose of IMG-7...
BCIQ Company Profiles
BCIQ Target Profiles